A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.
Eligibility criteria
Qualifiers
Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
Disqualifiers
None
Trial design
Treatments tested in this trial
- MRI
- Endoscopic ultrasound
Treatment groups
79 Participants
are divided into 1 treatment groupSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov